Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer’s disease early detection and differential diagnosis in patients with mild cognitive impairment (CROSBI ID 223162)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Babić Leko, Mirjana ; Borovečki, Fran ; Dejanović, Nenad ; Hof, Patrick R. ; Šimić, Goran Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer’s disease early detection and differential diagnosis in patients with mild cognitive impairment // Journal of alzheimers disease, 50 (2016), 3; 765-778. doi: 10.3233/JAD-150705

Podaci o odgovornosti

Babić Leko, Mirjana ; Borovečki, Fran ; Dejanović, Nenad ; Hof, Patrick R. ; Šimić, Goran

engleski

Predictive value of cerebrospinal fluid visinin-like protein-1 levels for Alzheimer’s disease early detection and differential diagnosis in patients with mild cognitive impairment

Visinin-like protein 1 (VILIP-1) recently emerged as a potential biomarker of Alzheimer’s disease (AD). This neuronal calcium sensor protein previously used as a marker of acute ischemic stroke is elevated in the cerebrospinal fluid (CSF) of AD patients. The goal of this study was to assess CSF VILIP-1 potential in early AD diagnosis and in differentiating MCI patients with and without risk of AD. Additionally, we tested VILIP-1 ability to differentiate AD from other primary causes of dementia, and predict the progression of AD-related cognitive decline. VILIP-1 levels were compared with five CSF AD biomarkers (t- tau, Aβ1-42, p-tau181, p-tau199, and p- tau231).VILIP-1 successfully differentiated two MCI patient groups characterized by absence or presence of pathological levels of these CSF biomarkers, except for t-tau.VILIP-1/Aβ1-42 and VILIP-1/p-tau181ratios also differentiated MCI patients with pathological CSF biomarker levels. However, there was no difference in VILIP-1 levels between AD and MCI patients. VILIP-1/Aβ1-42 and VILIP-1/p-tau231 ratios reached high sensitivities (above 70%) and very high specificities (above 85%) in differentiating AD patients from HC. Additionally, VILIP-1 differentiated AD from patients with Lewy body disease with 77.1% sensitivity and 100% specificity. VILIP-1 potential as a prognostic biomarker of cognitive decline in AD was also proved since VILIP-1/t-tau, VILIP-1/ptau181 and VILIP-1/p- tau231ratios correlated with MMSE scores. These data indicate that VILIP-1 alone or in combination with other AD CSF biomarkers represent a valuable marker for the early diagnosis of AD, recognition of MCI patients at higher risk to develop dementia, and in differentiating AD from LBD.

Visinin-like protein 1; dementia; biomarker; mild cognitive impairment; Alzheimer’s disease; cerebrospinal fluid; early diagnosis

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

50 (3)

2016.

765-778

objavljeno

1387-2877

10.3233/JAD-150705

Povezanost rada

Temeljne medicinske znanosti

Poveznice
Indeksiranost